Next Article in Journal
Emotional Exhaustion in Housewives and Alzheimer Patients’ Caregivers: Its Effects on Chronic Diseases, Somatic Symptoms and Social Dysfunction
Previous Article in Journal
Do Health-Related Quality of Life and Pain-Coping Strategies Explain the Relationship between Older Women Participants in a Pilates-Aerobic Program and Bodily Pain? A Multiple Mediation Model
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJERPH
Volume 16
Issue 18
10.3390/ijerph16183251
ijerph-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Role of Momordica charantia in Resisting Obesity

by
Meiqi Fan
1,†,
Eun-Kyung Kim
1,†,
Young-Jin Choi
1,
Yujiao Tang
1,2 and
Sang-Ho Moon
1,*
1
Division of Food Bioscience, College of Biomedical and Health Sciences, Konkuk University, Chungju 27478, Korea
2
School of Bio-Science and Food Engineering, Changchun University of Science and Technology, Changchun 130–600, China
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Environ. Res. Public Health 2019, 16(18), 3251; https://doi.org/10.3390/ijerph16183251
Submission received: 1 August 2019 / Revised: 28 August 2019 / Accepted: 2 September 2019 / Published: 4 September 2019
Browse Figures
Review Reports Versions Notes

Abstract

:
Momordica charantia (M. charantia), commonly known as bitter gourd, bitter melon, kugua, balsam pear, or karela, is a tropical and sub-tropical vine belonging to the Cucurbitaceae family. It has been used to treat a variety of diseases in the traditional medicine of China, India, and Sri Lanka. Here, we review the anti-obesity effects of various bioactive components of M. charantia established at the cellular and organismal level. We aim to provide links between various bioactive components of M. charantia and their anti-obesity mechanism. An advanced search was conducted on the worldwide accepted scientific databases via electronic search (Google Scholar, Web of Science, ScienceDirect, ACS Publications, PubMed, Wiley Online Library, SciFinder, CNKI) database with the query TS = “Momordica charantia” and “obesity”. Information was also obtained from International Plant Names Index, Chinese Pharmacopoeia, Chinese herbal classic books, online databases, PhD and MSc dissertations, etc. First, studies showing the anti-obesity effects of M. charantia on the cells and on animals were classified. The major bioactive components that showed anti-obesity activities included proteins, triterpenoids, saponins, phenolics, and conjugated linolenic acids. Their mechanisms included inhibition of fat synthesis, promotion of glucose utilization, and stimulation of auxiliary lipid-lowering activity. Finally, we summarized the risks of excessive consumption of M. charantia and the application. Although further research is necessary to explore various issues, this review establishes the therapeutic potential of M. charantia and it is highly promising candidate for the development of anti-obesity health products and medicines.

1. Introduction

According to World Health Organization (WHO), the incidence of obesity has increased by more than twofold since 1980. In June 2013, the American Medical Association officially regarded obesity as a disease [1]. Meanwhile, in 2014, more than 1.9 billion adults were overweight, including 600 million obese people [2,3]. Moreover, obesity is one of the major risk factors for the development of chronic diseases, such as hypertension, dyslipidemia, diabetes mellitus type 2, cardiovascular disease, insomnia, and apnea [4]. Therefore, obesity has become a major concern for the entire society. Although obesity can be treated with drugs and surgery, they may cause severe side effects in the body [5].
In recent years, increased attention is being paid to the development of novel therapies for the treatment of obesity [6,7]. Changes in lifestyle and restrictions on fat intake are considered to be the useful to manage obesity. However, owing to the accelerated pace of modern life, increased stress, and the concerns regarding the safety and tolerability of anti-obesity drugs, anti-obese effects of functional food are being explored. Currently, the development and utilization of plant resources are actively pursued in the field of functional food. Therefore, research on natural products and their anti-obesity activities has become a major topic of interest in the recent years.
Momordica charantia (M. charantia), commonly known as bitter gourd, bitter melon, kugua, balsam pear, or karela, is a climber belonging to the Cucurbitaceae family. It bears oblong fruits resembling cucumber, and the tender fruits are emerald green in color and turn to orange-yellow on ripening [8,9,10]. As a medicinal and edible vegetable, M. charantia has been used in the traditional medicine of China, India, and Sri Lanka for a long time to treat a variety of diseases [11,12,13]. There are different varieties of M. charantia with different growing environments and different growing sites [14]. In traditional Chinese treatments, M. charantia fruits, seeds, stem, and leaves are used as medicine for intestinal diseases, hypoglycemia, cancer, and some of viral infections. In India, Sri Lanka, and other countries, M. charantia is used to prepare nutritious food, hypoglycemic drugs, emetics, and laxative drugs [15]. Modern medical research shows that M. charantia exhibits anti-tumor, hypoglycemic, hypolipidemic, anti-oxidant, anti-viral, anti-bacterial, immune regulation, and other effects [16]. The active ingredients isolated from M. charantia include triterpenes, steroids, polysaccharides, proteins, peptides, and alkaloids [17]. Lakholia, a physician, was probably the first to document the therapeutic effect of M. charantia in 1956, using himself as the subject [18]. Subsequently, several studies have shown that M. charantia extract has anti-obesity activity, thus, exhibits high clinical value [19,20,21]. However, only a few review articles are available on this subject. The accumulating evidence indicates some papers show contradictory results. This has to do with the complex metabolic mechanisms of obesity. Also, this makes it difficult to elucidate the anti-obesity effect of M. charantia.
In this review, we discuss the inhibitory activity of M. charantia on the accumulation of fat, in addition to the major mechanisms of the corresponding bioactive substances. Our aim was to summarize the literature findings that provide the fundamental ideas for efficient processing and utilization of M. charantia for anti-obesity treatment.

2. Anti-Obesity Components of M. charantia

2.1. Saponins and Triterpenes

Saponins are plant secondary metabolites that occur in the roots, stems, leaves, seeds, and other plant tissues of a wide range of plant sources [22]. Saponins are classified into two broad categories, namely, steroidal saponins and triterpenoid saponins [23]. Sugimoto et al., found that triterpenes extracted from the leaves of Hollyhock using methanol, can inhibit the hydrolytic activity of pancreatic lipase to achieve the anti-obesity effect [24]. IC50 value of the triterpenoid saponin extract that could inhibit pancreatic lipase hydrolysis activity was 3.63 mg/mL [25]. Zhao et al., found that the Campanulaceae saponins rich diet can reduce the body weight of mice on high-fat diet [26]. As early as 1986, it was found that saponins in M. charantia seeds ameliorated obesity by improving insulin sensitivity and glucose homeostasis. [27].
The M. charantia roots, stems, leaves, and fruits contain saponins, mainly triterpenoid saponins. Experiments have shown that the total content of saponins in M. charantia seeds is approximately 0.432% [28]. Many types of saponins have been isolated from M. charantia, including cucurbit, oleanane-type, ursulan type, stigmasterol, cholesterol, and sitosterol saponins [29,30,31]. These ingredients have been found to reduce visceral fat weight and glucose levels, promote oxidation in liver and adipose tissue, and significantly lower blood TG levels [32,33,34,35]. In 1980, subsequent to the extraction of bitter ginseng, Okabe H isolated broad bean glycosides, M. charantia saponin-A and -B [36]. In 1981, Miyahara Y. et al. isolated saponin-C, -D, and -E from M. charantia extract [37]. In 1982, Okabe H. et al., isolated saponins-G, -F1, -F2, -I, -K, and -L from the extract of immature fruit of M. charantia [38,39]. Meanwhile, a saponin-rich fraction isolated from M. charantia was also found to lower blood sugar and small intestine disaccharidase activity in rats [40]. In 1984, Yasuda M. et al., isolated momordicine-I, -II, and -III from stem and leaf extracts of M. charantia [41]. They also isolated M. charantia glycoside-A and -B [42]. In 1995, Chang et al., isolated four compounds from the M. charantia fruit extract. Among these, three compounds were tetracyclic triterpenoid fennel compounds (M. charantia glycosides -F1, -G, and -I) [43]. In 1997, Begum S. et al., used the fresh extract M. charantia to obtain momordicine, momordicinin, and momordicilin [44]. In 2001, Toshiyuki M. et al., used the extract of M. charantia and isolated goyaglycoside -a, -b, -c, -d, -e, -f, -g, and -h as well as goyasaponin -I, -II, and -III [45]. In 2010, a new anti-diabetic formulation with M. charantia active ingredients, such as momordicines and glycosides, was developed [46]. In 2005, Tian et al., crushed fresh M. charantia, separated the extract and identified momordicoside-A [47]. In 2007, Pan et al., isolated three compounds from the dry and immature fruits of M. charantia, namely, germanicyl acetate, aglycone of momordicoside-I and -L [48]. In the same year, Guan et al. used the immature fruit extract of M. charantia and 95% ethanol refluxing, to obtain aglycones, such as momordicoside-F1 and -I [49]. Momordicosides have been shown to enhance fatty acid oxidation in in vivo models [50]. Studies have also shown that saponins inhibit pancreatic lipase activity and are considered to have anti-obesity and cholesterol-lowering properties [51]. In 2008, Cheng et al., isolated 26, 27-dihydroxy lanolin-7, 9 (11), 24-triene(24R)-cyclohexanone-3α, 24R, 25-triol, which is saponin, from the extract of M. charantia stem and leaf [52].
Saponins and triterpenes isolated from M. charantia, are presented in Figure 1.

2.2. Phenolics and Flavonoids

The phenolic compounds isolated from M. charantia were quinic acid, protocatechuic acid, ascorbic acid, gallic acid, chlorogenic acid, catechin, syringic acid, caffeic acid, rutin, 4-coumaric acid, myricetin, gentisic acid, vanillic acid, coumaric acid, t-cinnamic acid, and p-methoxy-benzoic acid. These have been found to exhibit anti-oxidant activity [53,54,55]. The flavonoid compounds have a polyphenol structure which is present in M. charantia in 2 forms, namely, free-aglycones and glycosides that bind to sugars [56]. The concentration of flavonoids in the ethanol extract and the water extract of M. charantia was 44.0 and 62.0 mg/g, respectively, while the concentration of polyphenols was 68.8 and 51.6 mg/g, respectively [57]. However, there is no clear data on the anti-obesity activity of phenols and flavonoids in M. charantia.
Meanwhile, the potential anti-obesity effects of phenolic compounds in animals have been reported in several studies. Chen et al. oral administration of a dose of polyphenol (100 mg/kg BW) to mice for 30 days and found that the body weight of mice and serum TC levels were significantly reduced compared with that of the control group [58]. Further, several flavonoids have been shown to play an important role in the treatment of obesity. In one of the studies, the catechins (5.7 g/kg BW) were oral administered to mice for 4 weeks. It was observed that catechins can decrease the body weight, levels of serum biochemical indicators (TC and TG), and levels of liver lipid [59]. In summary, several in vivo experimental results showed that the administration of phenolic compounds exhibited similar effect as that of lipid-lowering diet on mice. Although, M. charantia contains lots of phenols and flavonoids mentioned above, the bioactivity of phenols and flavonoids in M. charantia is still curious. This provides a possibility for the future research of phenols and flavonoids in M. charantia.
Figure 2 illustrates the phenolic constituents isolated from M. charantia using high performance liquid chromatography (HPLC).

2.3. Unsaturated Fatty Acids

As the unsaturated fatty acids constitute a major component of the body fat, their impact on lipid metabolism is a topic of interest worldwide. The unsaturated fatty acids inhibit the activity of fatty acid synthase (FAS), diglyceride transacylase (DGAT), and hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase. They promote the oxidative decomposition of fatty acids to inhibit glycerol TG synthesis, to down-regulate low-density lipoprotein (LDL) receptors in the liver, and to inhibit total cholesterol (TC) synthesis and absorption, thus, reducing serum TG and TC content [60,61]. Takada et al. showed that unsaturated fatty acids could stimulate rat liver peroxidase and can participate in the induction of uncoupling protein (UCP) and enhance β-oxidation in mitochondria in the rat liver, thereby accelerating the breakdown and clearance of lipids in the liver, and subsequently reducing the body fat deposition [62]. Baillie et al., found that dietary supplementation with fish oil induces peroxisomal fatty acid oxidation of skeletal muscle and increases UCP3 levels by a factor of 2, thereby reducing fat and protein deposition [63].
The proportion of unsaturated fatty acids in the M. charantia is high. The ratio of monounsaturated fatty acid content to total fatty acid content is approximately 20.1%, and the proportion of polyunsaturated fatty acid is approximately 64.3% (Figure 3). At present, nine kinds of unsaturated fatty acids have been extracted from M. charantia [56]. M. charantia seed oil is a unique as it contains 9cis, 11trans, 13trans-conjugated linolenic acid (9c, 11t, 13t-CLN) at high levels [64]. Ahmad et al., have tested α-glucosidase and α-amylase inhibitory activity and showed unusually high amounts of C18-0 (stearic acid, 62.31% of total fatty acid). C18-1 (oleic acid) and C18-2 (linoleic acid) were the other major fatty acid detected (12.53% and 10.40%, respectively). Other fatty acids detected in the analysis included C10-0 (0.53%, capric acid), C12-0 (0.45%, lauric acid), C16-0 (4.72%, palmitic acid) and C20-0 (5.3%, arachidic acid) [65]. In 2001, Noguchi et al. studied the effects of dietary fat consisted of soybean oil + 2.0% M. charantia seed oil on blood and liver fat metabolism and found that the intake of M. charantia seed extract can increase the content of linoleic acid (c-9, t-11-CLA) in the liver and in turn, decreases the free fatty acids in the blood [66]. In 2011, Gadang et al. found that fed AIN-93M diet modified to contain 3.0% (wt/wt) ground M. charantia seed for 100 days can promote the expression of peroxisome proliferator-activated receptor Y gene in the adipose tissue, reduce the expression of nuclear factor kappa B and further alleviate the symptoms associated with metabolic syndromes [67]. In 2012, a study by Chan et al. showed that containing 15% M. charantia extract diet reduces accumulation of body fat by regulating protein kinase activity and programmed cell death in adipocytes [68]. Moreover, containing 20% M. charantia seed extract diet extract exhibits the weight loss should be due to white adipose tissue degradation, inflammation and browning effect [69]. In 2017, Chen et al. found that the anti-adiposity function of M. charantia seed oil was solely attributed to its fatty acid fraction and that the FFA form was more effective than the TG form [70].

3. Anti-Obesity Mechanism of M. charantia

Anti-obesity mechanism of M. charantia was summarized in the Table 1.

3.1. Inhibition of the Synthesis of Fat

Fat synthesis is considered to be a key step in the development of obesity and regulating this step would effectively control the progression of obesity [89]. Currently, 3T3-L1 adipocytes are the important models used globally for studying the molecular mechanism of adipogenesis. The data showed that the 50% Ethanolic Extract of M. charantia is potent inhibitor of lipogenesis and stimulator of lipolysis in 3T3-L1 pre-adipocytes [90]. In 3T3-L1 cell differentiation studies, it has been found that adipogenesis is a highly elaborate regulatory process that involves a variety of transcription factors, such as C/EBPα and PPARγ) and lipid metabotropic proteins, such as, GluT-4, adiponectin, and leptin) [91,92].
Tan et al. showed that treatment of L6 myotubes and 3T3-L1 adipocytes with the extract of M. charantia in ethanol could restrain the fat synthesis. The bioactive compounds in M. charantia can stimulate glucose transporter 4 (GLUT-4) to migrate to the cell membrane and mediate glucose uptake by increasing the adenosine monophosphate-activated protein kinase (AMPK) activity. Fatty acid oxidation, insulin tolerance, and insulin resistance were assessed by glucose tolerance test in mice. The results showed that M. charantia extract containing stearoyl-glycosides could increase fatty acid oxidation and glucose distribution. Thus, it can be concluded that bioactive compounds in M. charantia have a role in the prevention of obesity [71].
Peroxisome proliferator-activated receptor gamma (PPARγ) belongs to nuclear hormone receptor superfamily PPARs. PPARγ is overexpressed in adipocytes, vascular smooth muscle cells, macrophages, cardiomyocytes, and endothelial cells [93,94,95]. Overexpression of PPARγ gene transforms non-adipogenic embryonic fibroblasts and myoblasts into adipocytes [96].
Roffey et al., used 3T3-L1 adipocyte model to demonstrate that even the M. charantia-water extract can promote the utilization of glucose and secretion of adiponectin. The combination treatment of cells with 0.2 mg/mL M. charantia water extract and 0.5 nM insulin was associated with significant (p < 0.05) increase in the glucose uptake (61%) and adiponectin secretion (75%) in comparison to those observed in the control cells [73]. Popovich et al., treated 3T3-L1 cells with methanol extract of M. charantia. The results suggested that the concentration of TG was slightly decreased, the release of lactate dehydrogenase was increased, and the expression of adiponectin and PPARγ was blocked in the cells. The number of G2/M phase cells was increased and that of G1 phase cells was decreased, thus, reducing the accumulation of fat in the cells [72]. This is contrary to previous reports. It is likely that M. charantia does not interact directly with 3T3-L1 cells, such as the thiazolidinediones reported [97,98], Alternately, it was found that lipid accumulation in 3T3-L1 cells and expression of PPARγ were reduced when AMP kinase was activated [99,100]. It is thus possible that activation of AMP kinase may also play a role in reducing lipid accumulation observed in this study.
PPAR-γ has been known to play an important role in the regulation of adipocyte differentiation and various other metabolic pathways, such as sugar and fat metabolism. The GLUT-4 dysfunction, owing to aberrations in the glucose transport mechanism, is an important cause of adipose tissue insulin resistance [101].
In a study by Shih et al., the effects of M. charantia on skeletal muscle GLUT-4 were observed. They found that M. charantia extract could increase the expression of PPARγ in adipose tissue [74].

3.2. Promotion of the Utilisation of Glucose

Yibchokanun et al., performed experiments on 3T3 adipocytes and revealed that M. charantia ethanol extract significantly increased the glucose uptake after 4 and 6 h of cell incubation as the M. charantia extract can promote insulin secretagogue activity [75]. He et al. performed in vitro activation experiments and showed that M. charantia polysaccharides increased PPARγ and PPARδ activation to 1.7 and 2.0-fold, respectively [76].
Phosphatidylinositol 3-kinase (PI3K) is a key signaling molecule in the process of insulin signal transduction. Activated PI3K can accelerate the transport of GLUT-4 and GLUT-1 to the membrane, and regulate the effect of glucose on myocytes, adipocytes, and hepatocytes, by inhibiting gluconeogenesis through inhibition of the activity of enolase pyruvate kinase. Kumar et al., treated L6 skeletal muscle cells grown in 2-deoxy-D-[1-3H] glucose, with the combination of M. charantia water extract and chloroform (6 μg/mL) up to 2.8, 3.6, and 3.8 times of original level of extract and showed that upregulation of the glucose uptake was approximately twice as fast as uptake of insulin and rosiglitazone [77].
AMPK promotes GLUT-4 transport from the cytoplasm to the cell membrane, thereby increasing glucose uptake and fatty acid oxidation. The enhanced expression of GLUT-4 in the central part of peripheral tissues leads to enhancement in the utilization of glucose, which is probably related to the activation of AMPK pathway. Studies by Iseli and others have found that purification of the ethanol extracts obtained from M. charantia cells, prior to treatment of the model cells can increase AMPK activity [102]. The activation of AMPK pathway is the initiating factor of insulin. Further, Klomann et al., found that M. charantia extract can increase the expression of GLUT-4 and glucose uptake [103]. Han et al., findings demonstrated that the new cucurbitane-type triterpenoids isolated from the ethanol extract of M. charantia enhances potential for prevention and management of obesity by improving insulin sensitivity and glucose homeostasis. Their results showed that M. charantia extract promotes glucose utilization by increasing glucose uptake into the skeleton [78].
AMPK activates the translocation of GLUT-4, increases muscle responses to insulin, and stimulates fatty acid oxidation. In vivo experiments by Miura et al. have shown that treating obese mice with water extract of M. charantia resulted in the strong activation of skeletal muscle AMPK. The water extract of M. charantia was fed to mice at 100 mg/kg and 20 mg/kg BW and this treatment resulted in an increase in AMPK levels by 1.6-fold [79]. Zhu et al., found that crude extract of M. charantia could prominently reduce fasting plasma glucose (21.40 to 12.54 mmol/L) and serum insulin (40.93 to 30.74 mIU/L) in diabetic rats [80].
The inhibition of fat synthesis and promotion of glucose utilization function of M. charantia is related to adiponectin, leptin, GLUT-4, AMPK, PPARγ, C/EBPα, and PI3K. By promoting their regulation, it promotes fatty acid oxidation and inhibits adipocyte differentiation to achieve anti-obesity effect (Figure 4).

3.3. Auxiliary Lipid-Lowering Activity

Hyperlipidemia refers to the phenomenon of hypercholesterolemia and high TG levels in the blood, or low levels of HDL-c. Hyperlipidemia is one of the metabolic characteristics of obesity.
Hussain et al., carried out in vivo biological investigations with an ethanolic extract of M. charantia, to evaluate both its anti-hyperlipidemic activity and serum uric acid level-reducing potential. Results showed that ethanolic extract of M. charantia, at a dose of 200 mg/kg BW, significantly (p < 0.05) reduced cholesterol and TG levels when co-administrated with 20% fat and normal feed, which was comparable with data obtained from standard Atorvastatin treatment [81]. Studies by Xu and others have shown that M. charantia fruit powder prevents high-fat diet-induced metabolic disorders in mice. Their results also showed that both water-soluble and insoluble parts of M. charantia can reduce TG levels in obese mice [82].
The studies by Ahmad et al., suggested that the levels of non-esterified cholesterol and phospholipids in the serum of diabetic rats was twice as high as that of the normal control group. The TG (TG) level was four times more and the level of HDL-c was 50% more in diabetic rats than those in the control group. The crude extract of M. charantia treatment administered to diabetic rats could reduce the elevated levels of serum non-esterified cholesterol, phospholipids, TG, and HDL-c [83]. This effect probably occurs through the regulation of TG, cholesterol, and phospholipid metabolism in the liver and other organs, and increase in insulin secretion. Experiments by Welihinda et al., showed that the treatment of M. charantia fruit extract could increase the insulin secretion in the pancreas of diabetic rats, and the insulin-activated lipase hydrolyses the lipoprotein-bound TG [84]. Lipase enzyme cannot be activated in insulin-deficient individuals, so it cannot reduce TG levels. Senanayake et al., studied the effects of three different varieties (Koimidori, Powerful-Reishi, and Hyakunari) of M. charantia and those of methanol fraction extract of Koimidori variety on serum and liver TG in rats. Koimidori extract (3%) was found to be the most effective in reducing hepatic TG levels in experimental animals, and the effects of Hyakunari and Powerful-Reishit were successively reduced. Koimidori extracts obtained from n-hexane, acetone, and methanol, respectively, were administered to experimental animals and compared with those of Koimidori without isolation. The 1% methanol extract acts as a 3% Koimidori crude extract, concluding that the active ingredient that reduces liver TG levels in the M. charantia variety Koimidori is enriched in the methanol extract [85]. Studies by Jayasooriya have shown that the diet containing cholesterol tends to decrease HDL-c levels in the body, whereas consumption of M. charantia can cause an increase in serum HDL-c levels regardless of dietary cholesterol levels [86].
While M. charantia powder (organic solvent extraction) has been shown to affect serum HDL levels, but it shows only a minor effect on serum TG levels [85]. Additionally, M. charantia extract significantly reduces the total liver cholesterol levels and TG levels. M. charantia extract shows a dose-response relation while reducing the TG levels. Abd et al., found that M. charantia extract can significantly reduce the serum levels of cholesterol and TGs in alloxan-induced diabetic mice [87]. Ahmad et al., performed an experiment to understand the effect of the M. charantia fruit extract on STZ-induced diabetic rats. Elevated levels of HDL-c can result in increased lipid flow in tissues or increased free fatty acid intake and storage capacity to achieve the effect of lowering serum phospholipid and TG level [83]. Pan et al., treated hyperlipidemia model mice for 4 weeks with water extract of M. charantia and found that it can significantly reduce the liver fat accumulation in mice with hyperlipidemia and significantly lower the serum TC and TG concentrations [88]. Studies by Chanda and others have shown that among various parts of M. charantia, whole fruit part in a dose of 300 mg/kg body weight found to be suitable in reduction in cholesterol, increase in HDL and minimize the amount of LDL and TG [104].
Thus, these studies demonstrate that the effects of M. charantia on the liver and its serum auxiliary lipid-lowering activity may be mediated by the regulation of TG, cholesterol, and phospholipid metabolism in the liver and other organs, and increase in insulin secretion (Figure 5). However, in the previous studies, M. charantia showed a negligible effect on serum TG levels. The reason for this phenomenon may be due to the variations in experimental conditions.

4. Risk of Over-Consumption of M. charantia

Since ages, M. charantia has been widely recognized and used as medicinal edible plant. However, only a few studies have shown safety issues associated with excessive consumption of M. charantia [105,106,107]. Leung et al. and Raman et al. reviewed the possible side effects caused by excessive consuming M. charantia juice, including children consuming large amounts of M. charantia tea after a period of hypoglycemic coma and convulsions. They reviewed that long-term consumption of M. charantia will lead to the glucose-6-phosphate dehydrogenase deficiency and risk of fava bean disease in humans. The toxic lectin in the rind and pulp of M. charantia may inhibit the synthesis of proteins in the intestine and this effect may be related to the separation of Vicia faba glycosides present in the M. charantia seeds [108,109]. Nadkarni et al., measured the blood pressure, blood glucose, liver and kidney function, and other related indicators, after the consumption of 500 mL of M. charantia juice concentrate, and found that M. charantia juice can cause an acute gastric ulcer and intestinal bleeding. They speculated that the toxic substances producing these effects might be alkaloids, lectins, or charantin [110].

5. Current and Future Applications of M. charantia in the Anti-Obesity Treatment

In order to maximize the activity of M. charantia components and avoid the risk of over-consumption, the development of inventive processing method is needed. In order to obtain a new sugar-free M. charantia yoghurt, Zhang et al. mixed M. charantia juice and fresh milk as the raw materials at a 3:7 ratio along with Lactobacillus bulgaricus and Streptococcus thermophilus at a 1:1 ratio as the starter inoculum for fermentation. This yogurt with M. charantia fragrance was much sweeter and sourer than others. This product exhibits a high promotional value since both M. charantia and yoghurt possess numerous benefits to public health [111]. Flour containing 4% M. charantia powder was used to form a new table staple food-balsam health noodles [112]. In the fat-lean ratio was 1:4, M. charantia mass fraction was 9%, starch mass fraction was 12%, compound sausage with M. charantia not only reduced the production costs, but also improved the nutritional value [113]. M. charantia, peanuts and xylitol-based raw materials are used to prepare low-sugar health drinks [114]. A healthy drink is produced by mixing 30% M. charantia juice and 15% Campanulaceae extract added with 8% sugar and 0.1% citric acid [115]. M. charantia as raw material, zinc gluconate as color protector, and β-cyclodextrin as bitter embedding agent are used to produce M. charantia granules [116]. The best formula of effervescent tablets was determined as follows: M. charantia powder 4.0%; sucrose 17.8%, sweet 3.6%, sodium bicarbonate 31.1%, citric acid 6.7%, and maltodextrin 35.6%. The M. charantia effervescent tablet drinks have good sensory quality and unique taste; its bitter taste was masked, and it is easily accepted by consumers [117]. Fresh milk and M. charantia juice at 8:2 ratio, added with 9% sucrose and 0.15% compound stabilizer produces a M. charantia milk drink [118]. A solution of M. charantia juice and apricot juice at 2:7 ratio, produces a compounded drink [119]. A solution of 10% M. charantia juice, 20% citrus juice, 7% sugar, 3% honey, and 0.2% citric acid is formulated into a citrus-M. charantia compound fruit and vegetable drink [120].
Meanwhile, there are few food product using bioactive components of M. charantia for anti-obesity. Hopefully, this review motivates to develop the related products.

6. Conclusions

Recently, several developments at the interface of natural product chemistry and medicine have demonstrated that various plant extracts have good anti-obesity properties and are of interest due to their low toxicity or non-toxic benefits. In spite of its regular use as medicinal plant in many Asian countries, active ingredients of M. charantia have not been identified or studied systematically studied by implementing novel strategies and technologies. Although there are many studies on the mechanism of anti-adiposity at the cellular level, its mechanism of action in the animals is rarely studied and is a controversial subject. For instance, the inhibitory effect of the M. charantia extract on leptin expression contradicts with its anti-adiposis effect. Only a few experiments on the processing of M. charantia have been conducted; however, these could provide the basis for further developments. Moreover, there is no large-scale industrialized application at present and there are only a few reports on the comprehensive utilization of M. charantia to fully explore their potential as anti-obesity agent.
In this review, we summarized the biochemical components of M. charantia that show anti-obesity activity and their mechanisms of action. Additionally, we described the relevant current progress in this area. Further, we verified the function and synergistic effects of various components of M. charantia and provided an account on the subsequent processing methods that could lead to comprehensive utilization of M. charantia.

Author Contributions

M.F. wrote the original draft. Y.-J.C. participated in literature analysis and manuscript editing. Y.T. contributed to the conception of the study and editing of the manuscript. E.-K.K. and S.-H.M. designed and reviewed the main structure of the manuscript. All authors reviewed and approved the final version of manuscript.

Funding

This research received no external funding.

Acknowledgments

This paper was supported by Konkuk University in 2018.

Conflicts of Interest

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

  1. Breymaier, S. AMA Adopts New Policies on Second Day of Voting at Annual Meeting; American Medical Association: Chicago, IL, USA, 2013. [Google Scholar]
  2. World Health, Organization. Global Status Report on Road Safety 2015; World Health Organization: Geneva, Switzerland, 2015. [Google Scholar]
  3. Rodgers, R.J.; Tschöp, M.H.; Wilding, J.P. Anti-obesity drugs: Past, present and future. Dis. Model. Mech. 2012, 5, 621–626. [Google Scholar] [CrossRef] [PubMed]
  4. Kang, Y.S. Obesity associated hypertension: New insights into mechanism. Electrolytes Blood Press. 2013, 11, 46–52. [Google Scholar] [CrossRef] [PubMed]
  5. Schauer, P.R.; Bhatt, D.L.; Kirwan, J.P.; Wolski, K.; Aminian, A.; Brethauer, S.A.; Navaneethan, S.D.; Singh, R.P.; Pothier, C.E.; Nissen, S.E. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. New Engl. J. Med. 2017, 376, 641–651. [Google Scholar] [CrossRef] [PubMed]
  6. Hurt, R.T.; Frazier, T.H.; Mundi, M.S. Novel nonsurgical endoscopic approaches for the treatment of obesity. Nutr. Clin. Pract. 2017, 32, 493–501. [Google Scholar] [CrossRef] [PubMed]
  7. Schinzari, F.; Tesauro, M.; Cardillo, C. Endothelial and perivascular adipose tissue abnormalities in obesity-related vascular dysfunction: Novel targets for treatment. J. Cardiovasc. Pharmacol. 2017, 69, 360–368. [Google Scholar] [CrossRef]
  8. Behera, T.K.; Behera, S.; Bharathi, L.K.; John, K.J.; Simon, P.W.; Staub, J.E. Bitter gourd: Botany, horticulture, breeding. Hortic. Rev. 2010, 37, 101. [Google Scholar] [CrossRef]
  9. Raina, K.; Kumar, D.; Agarwal, R. Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy. Seminars in Cancer Biology 2016, 116–129. [Google Scholar] [CrossRef] [PubMed]
  10. Joseph, B.; Jini, D. Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian Pac. J. Trop. Dis. 2013, 3, 93–102. [Google Scholar] [CrossRef]
  11. Zhang, F.; Lin, L.; Xie, J. A mini-review of chemical and biological properties of polysaccharides from Momordica charantia. Int. J. Biol. Macromol. 2016, 92, 246–253. [Google Scholar] [CrossRef]
  12. Nagarani, G.; Abirami, A.; Siddhuraju, P. Food prospects and nutraceutical attributes of Momordica species: A potential tropical bioresources—A review. Food Sci. Hum. Wellness 2014, 3, 117–126. [Google Scholar] [CrossRef]
  13. Xu, X.; Shan, B.; Liao, C.-H.; Xie, J.-H.; Wen, P.-W.; Shi, J.-Y. Anti-diabetic properties of Momordica charantia L. polysaccharide in alloxan-induced diabetic mice. Int. J. Biol. Macromol. 2015, 81, 538–543. [Google Scholar] [CrossRef] [PubMed]
  14. Thakur, V. Yield and yield contributing traits of bitter gourd (Momordica charantia L.) genotypes. J. Pharmacogn. Phytochem. 2018, 7, 844–846. [Google Scholar]
  15. Senanayake, G.V.; Fukuda, N.; Nshizono, S.; Wang, Y.M.; Nagao, K.; Yanagita, T.; Iwamoto, M.; Ohta, H. Mechanisms underlying decreased hepatic triacylglycerol and cholesterol by dietary bitter melon extract in the rat. Lipids 2012, 47, 495–503. [Google Scholar] [CrossRef] [PubMed]
  16. Ahamad, J.; Amin, S.; Mir, S.R. Momordica charantia Linn.(Cucurbitaceae): Review on Phytochemistry and Pharmacology. Phytochemistry 2017, 11, 53–65. [Google Scholar]
  17. Wang, S.; Li, Z.; Yang, G.; Ho, C.-T.; Li, S. Momordica charantia: A popular health-promoting vegetable with multifunctionality. Food Funct. 2017, 8, 1749–1762. [Google Scholar] [CrossRef] [PubMed]
  18. Lakholia, A. The use of bitter gourd in diabetes mellitus. Antiseptic 1956, 53, 608–610. [Google Scholar]
  19. Dans, A.M.L.; Villarruz, M.V.C.; Jimeno, C.A.; Javelosa, M.A.U.; Chua, J.; Bautista, R.; Velez, G.G.B. The effect of Momordica charantia capsule preparation on glycemic control in Type 2 Diabetes Mellitus needs further studies. J. Clin. Epidemiol. 2007, 60, 554–559. [Google Scholar] [CrossRef] [PubMed]
  20. Tongia, A.; Tongia, S.K.; Dave, M. Phytochemical determination and extraction of Momordica charantia fruit and its hypoglycemic potentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM). Indian J. Physiol. Pharmacol. 2004, 48, 241–244. [Google Scholar] [PubMed]
  21. Yeh, G.Y.; Eisenberg, D.M.; Kaptchuk, T.J.; Phillips, R.S. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003, 26, 1277–1294. [Google Scholar] [CrossRef] [PubMed]
  22. Sparg, S.; Light, M.; Van Staden, J. Biological activities and distribution of plant saponins. J. Ethnopharmacol. 2004, 94, 219–243. [Google Scholar] [CrossRef]
  23. Haralampidis, K.; Trojanowska, M.; Osbourn, A.E. Biosynthesis of Triterpenoid Saponins in Plants. Adv. Biochem. Eng. Biotechnol. 2002, 75, 31–49. [Google Scholar]
  24. Sugimoto, S.; Nakamura, S.; Yamamoto, S.; Yamashita, C.; Oda, Y.; Matsuda, H.; Yoshikawa, M. Brazilian natural medicines. III. structures of triterpene oligoglycosides and lipase inhibitors from mate, leaves of Ilex paraguariensis. Chem. Pharm. Bull. 2009, 57, 257–261. [Google Scholar] [CrossRef] [PubMed]
  25. Lee, I.-A.; Lee, J.H.; Baek, N.-I.; Kim, D.-H. Antihyperlipidemic effect of crocin isolated from the fructus of Gardenia jasminoides and its metabolite crocetin. Biol. Pharm. Bull. 2005, 28, 2106–2110. [Google Scholar] [CrossRef] [PubMed]
  26. Zhao, H.; Sim, J.; Shim, S.; Ha, Y.; Kang, S.; Kim, Y. Antiobese and hypolipidemic effects of platycodin saponins in diet-induced obese rats: Evidences for lipase inhibition and calorie intake restriction. Int. J. Obes. 2005, 29, 983. [Google Scholar] [CrossRef]
  27. Ng, T.; Wong, C.; Li, W.; Yeung, H. Insulin-like molecules in Momordica charantia seeds. J. Ethnopharmacol. 1986, 15, 107–117. [Google Scholar] [CrossRef]
  28. Xu, B.; Dong, Y. Determination on total saponins of Momordica charantia L. by spectrophotometry. Food Sci. 2005, 10, 165–169. [Google Scholar]
  29. Yang, D.; Meng, D.L.; Cao, J.Q.; Zhao, Y.Q. Research progress on modern pharmacy and hypoglycemic effects of momordicosides. Chin. Tradit. Herb. Drugs 2013, 44, 3582–3592. [Google Scholar]
  30. Zhang, L.-J.; Liaw, C.-C.; Hsiao, P.-C.; Huang, H.-C.; Lin, M.-J.; Lin, Z.-H.; Hsu, F.-L.; Kuo, Y.-H. Cucurbitane-type glycosides from the fruits of Momordica charantia and their hypoglycaemic and cytotoxic activities. J. Funct. Foods 2014, 6, 564–574. [Google Scholar] [CrossRef]
  31. Hsiao, P.-C.; Liaw, C.-C.; Hwang, S.-Y.; Cheng, H.-L.; Zhang, L.-J.; Shen, C.-C.; Hsu, F.-L.; Kuo, Y.-H. Antiproliferative and hypoglycemic cucurbitane-type glycosides from the fruits of Momordica charantia. J. Agric. Food Chem. 2013, 61, 2979–2986. [Google Scholar] [CrossRef]
  32. Vadivel, V.; Venkatalakshmi, P.; Brindha, P. Anti-obesity potential of Indian traditional medicinal plants and their phytochemicals. In Medicinal Plants: Promising Future for Health and New Drugs, 1st ed.; Thangaraj, P., Ed.; CRC Press: Boca Raton, FL, USA, 2018; p. 22. [Google Scholar]
  33. Kalaivani, A.; Sathibabu Uddandrao, V.; Brahmanaidu, P.; Saravanan, G.; Nivedha, P.; Tamilmani, P.; Swapna, K.; Vadivukkarasi, S. Anti obese potential of Cucurbita maxima seeds oil: Effect on lipid profile and histoarchitecture in high fat diet induced obese rats. Nat. Prod. Res. 2018, 32, 2950–2953. [Google Scholar] [CrossRef]
  34. Brusaferro, A.; Cozzali, R.; Orabona, C.; Biscarini, A.; Farinelli, E.; Cavalli, E.; Grohmann, U.; Principi, N.; Esposito, S. Is it time to use probiotics to prevent or treat obesity? Nutrients 2018, 10, 1613. [Google Scholar] [CrossRef] [PubMed]
  35. Ghaedi, E.; Varkaneh, H.K.; Rahmani, J.; Mousavi, S.M.; Mohammadi, H.; Fatahi, S.; Pantovic, A.; Darooghegi Mofrad, M.; Zhang, Y. Possible anti-obesity effects of phytosterols and phytostanols supplementation in humans: A systematic review and dose–response meta-analysis of randomized controlled trials. Phytother. Res. 2019, 33, 1246–1257. [Google Scholar] [CrossRef] [PubMed]
  36. Okabe, H.; Miyahara, Y.; Yamauchi, T.; Miyahara, K.; Kawasaki, T. Studies on the constituents of Momordica charantia LI Isolation and characterization of momordicosides A and B, glycosides of a pentahydroxy-cucurbitane triterpene. Chem. Pharm. Bull. 1980, 28, 2753–2762. [Google Scholar] [CrossRef]
  37. Miyahara, Y.; Okabe, H.; Yamauchi, T. Studies on the constituents of Momordica charantia L. II. Isolation and characterization of minor seed glycosides, momordicosides C, D and E. Chem. Pharm. Bull. 1981, 29, 1561–1566. [Google Scholar] [CrossRef]
  38. Okabe, H.; Miyahara, Y.; Yamauchi, T. Studies on the constituents of Momordica charantia L. III. Characterization of new cucurbitacin glycosides of the immature fruits. Structures of momordicosides G, F1, F2 and I. Chem. Pharm. Bull. 1982, 30, 3977–3986. [Google Scholar] [CrossRef]
  39. Okabe, H.; Miyahara, Y.; YAMAUCHI, T. Studies on the constituents of Momordica charantia L. IV. Characterization of the new cucurbitacin glycosides of the immature fruits.(2) Structures of the bitter glycosides, momordicosides K and L. Chem. Pharm. Bull. 1982, 30, 4334–4340. [Google Scholar] [CrossRef]
  40. Oishi, Y.; Sakamoto, T.; Udagawa, H.; Taniguchi, H.; Kobayashi-Hattori, K.; Ozawa, Y.; Takita, T. Inhibition of increases in blood glucose and serum neutral fat by Momordica charantia saponin fraction. Biosci. Biotechnol. Biochem. 2007, 71, 735–740. [Google Scholar] [CrossRef]
  41. Yasuda, M.; Iwamoto, M.; Okabe, H.; Yamauchi, T. Structures of momordicines I, II and III, the bitter principles in the leaves and vines of Momordica charantia L. Chem. Pharm. Bull. 1984, 32, 2044–2047. [Google Scholar] [CrossRef]
  42. Zhu, Z.J.; Zhong, Z.C.; Luo, Z.Y.; Xiao, Z.Y. Study on the Active Ingredients of Momordica charantia L. J. Pharm. Sci. 1990, 25, 898–903. [Google Scholar]
  43. Fenggang, C.; Jianmei, L. Studies on the Antifertillty Chemical Constituents of Balsampear (Momordica charantia). Chin. Tradit. Herb. Drugs 1995, 6, 281–284. [Google Scholar]
  44. Begum, S.; Ahmed, M.; Siddiqui, B.S.; Khan, A.; Saify, Z.S.; Arif, M. Triterpenes, A sterol and A monocyclic alcohol from Momordica charantia. Phytochemistry 1997, 44, 1313–1320. [Google Scholar] [CrossRef]
  45. Murakami, T.; Emoto, A.; Matsuda, H.; Yoshikawa, M. Medicinal foodstuffs. XXI. Structures of new cucurbitane-type triterpene glycosides, goyaglycosides-a,-b,-c,-d,-e,-f,-g, and-h, and new oleanane-type triterpene saponins, goyasaponins I, II, and III, from the fresh fruit of Japanese Momordica charantia L. Chem. Pharm. Bull. 2001, 49, 54–63. [Google Scholar] [CrossRef] [PubMed]
  46. Afroze, M.; Kabiraz, M.; Islam, R.; Ghani, A. Chemical constituents and pharmacological properties of capsule gurmar-A new anti-diabetic formulation of Hamdard laboratories (Waqf) Bangladesh. Stamford J. Pharm. Sci. 2010, 3, 18–27. [Google Scholar] [CrossRef]
  47. Tian, B.-q.; Yang, Y.-p.; He, Z.-s.; Ye, Y. Chemical constituents of water-soluble part of Momordica charantia. Chin. Tradit. Herb. Drugs 2005, 5, 657–658. [Google Scholar]
  48. Hui, P.; Zhao, Y. Studies on the Hypoglycemic Constituents of Momordica charantia L. Asia-Pacific Tradit. Med. 2006, 1, 65–72. [Google Scholar]
  49. Guan, J.; Zhao, Y.Q. Chemical constituents in fruit of Momordica charantia. Chin. Tradit. Herb. Drugs 2007, 38, 1777–1778. [Google Scholar]
  50. Gul, T.; Balkhi, H.M.; Haq, E. AMPK: A potent target for treating obesity. Int. J. Pharm. Chem. Bio. Sci. 2013, 3, 801–813. [Google Scholar]
  51. Zhao, H.; Harding, S.; Marinangeli, C.; Kim, Y.; Jones, P. Hypocholesterolemic and anti-obesity effects of saponins from Platycodon grandiflorum in hamsters fed atherogenic diets. J. Food Sci. 2008, 73, H195–H200. [Google Scholar] [CrossRef]
  52. Lan-Ying, C.; Lin, T.; Fang, Y.; Shi-Gui, L.; Fang, C. Study on isolation of chemical components and structure from the shoot extract of Momordica charantia L. J. Sichuan Univ. (Na.t Sci. Ed.) 2008, 3, 645–650. [Google Scholar]
  53. Harinantenaina, L.; Tanaka, M.; Takaoka, S.; Oda, M.; Mogami, O.; Uchida, M.; Asakawa, Y. Momordica charantia constituents and antidiabetic screening of the isolated major compounds. Chem. Pharm. Bull. 2006, 54, 1017–1021. [Google Scholar] [CrossRef]
  54. Kenny, O.; Smyth, T.; Hewage, C.; Brunton, N. Antioxidant properties and quantitative UPLC-MS analysis of phenolic compounds from extracts of fenugreek (Trigonella foenum-graecum) seeds and bitter melon (Momordica charantia) fruit. Food Chem. 2013, 141, 4295–4302. [Google Scholar] [CrossRef] [PubMed]
  55. Horax, R.; Hettiarachchy, N.; Chen, P. Extraction, quantification, and antioxidant activities of phenolics from pericarp and seeds of bitter melons (Momordica charantia) harvested at three maturity stages (immature, mature, and ripe). J. Agric. Food Chem. 2010, 58, 4428–4433. [Google Scholar] [CrossRef] [PubMed]
  56. Zhi-zhou, L. Extraction and anti-oxidation property of flavones from Momordica charantia. Chin. J. Biochem. Pharm. 2007, 4, 264–266. [Google Scholar]
  57. De Melo, M.L.S.; Narain, N.; Bora, P.S. Characterisation of some nutritional constituents of melon (Cucumis melo hybrid AF-522) seeds. Food Chem. 2000, 68, 411–414. [Google Scholar] [CrossRef]
  58. Chen, Q.; Wu, X.; Liu, L.; Shen, J. Polyphenol-rich extracts from Oiltea camellia prevent weight gain in obese mice fed a high-fat diet and slowed the accumulation of triacylglycerols in 3T3-L1 adipocytes. J. Funct. Foods 2014, 9, 148–155. [Google Scholar] [CrossRef]
  59. Chan, P.T.; Fong, W.P.; Cheung, Y.L.; Huang, Y.; Ho, W.K.K.; Chen, Z.-Y. Jasmine green tea epicatechins are hypolipidemic in hamsters (Mesocricetus auratus) fed a high fat diet. J. Nutr. 1999, 129, 1094–1101. [Google Scholar] [CrossRef] [PubMed]
  60. Nestel, P.J. Fish oil and cardiovascular disease: Lipids and arterial function. Am. J. Clin. Nutr. 2000, 71, 228S–231S. [Google Scholar] [CrossRef]
  61. Broughton, K.S.; Morgan, L.J. Frequency of (n-3) polyunsaturated fatty acid consumption induces alterations in tissue lipid composition and eicosanoid synthesis in CD-1 mice. J. Nutr. 1994, 124, 1104–1111. [Google Scholar] [CrossRef]
  62. Takada, R.; Saitoh, M.; Mori, T. Dietary γ-linolenic acid-enriched oil reduces body fat content and induces liver enzyme activities relating to fatty acid β-oxidation in rats. J. Nutr. 1994, 124, 469–474. [Google Scholar] [CrossRef]
  63. Baillie, R.A.; Takada, R.; Nakamura, M.; Clarke, S.D. Coordinate induction of peroxisomal acyl-CoA oxidase and UCP-3 by dietary fish oil: A mechanism for decreased body fat deposition. Prostaglandins Leukot. Essent. Fatty Acids 1999, 60, 351–356. [Google Scholar] [CrossRef]
  64. Yasui, Y.; Hosokawa, M.; Sahara, T.; Suzuki, R.; Ohgiya, S.; Kohno, H.; Tanaka, T.; Miyashita, K. Bitter gourd seed fatty acid rich in 9c, 11t, 13t-conjugated linolenic acid induces apoptosis and up-regulates the GADD45, p53 and PPARγ in human colon cancer Caco-2 cells. Prostag. Leukotr. Ess. 2005, 73, 113–119. [Google Scholar] [CrossRef] [PubMed]
  65. Ahmad, Z.; Zamhuri, K.F.; Yaacob, A.; Siong, C.H.; Selvarajah, M.; Ismail, A.; Hakim, M.N. In vitro anti-diabetic activities and chemical analysis of polypeptide-k and oil isolated from seeds of Momordica charantia (bitter gourd). Molecules 2012, 17, 9631–9640. [Google Scholar] [CrossRef]
  66. Noguchi, R.; Yasui, Y.; Suzuki, R.; Hosokawa, M.; Fukunaga, K.; Miyashita, K. Dietary effects of bitter gourd oil on blood and liver lipids of rats. Arch. Biochem. Biophys. 2001, 396, 207–212. [Google Scholar] [CrossRef] [PubMed]
  67. Gadang, V.; Gilbert, W.; Hettiararchchy, N.; Horax, R.; Katwa, L.; Devareddy, L. Dietary bitter melon seed increases peroxisome proliferator-activated receptor-γ gene expression in adipose tissue, down-regulates the nuclear factor-κB expression, and alleviates the symptoms associated with metabolic syndrome. J. Med. Food 2011, 14, 86–93. [Google Scholar] [CrossRef]
  68. Chen, P.-H.; Chen, G.-C.; Yang, M.-F.; Hsieh, C.-H.; Chuang, S.-H.; Yang, H.-L.; Kuo, Y.-H.; Chyuan, J.-H.; Chao, P.-M. Bitter melon seed oil–attenuated body fat accumulation in diet-induced obese mice is associated with cAMP-dependent protein kinase activation and cell death in white adipose tissue. J. Nutr. 2012, 142, 1197–1204. [Google Scholar] [CrossRef] [PubMed]
  69. Hsieh, C.-H.; Chen, G.-C.; Chen, P.-H.; Wu, T.-F.; Chao, P.-M. Altered white adipose tissue protein profile in C57BL/6J mice displaying delipidative, inflammatory, and browning characteristics after bitter melon seed oil treatment. PLoS ONE 2013, 8, e72917. [Google Scholar] [CrossRef]
  70. Chen, G.-C.; Chen, W.-H.; Tseng, K.-T.; Chao, P.-M. The anti-adiposity effect of bitter melon seed oil is solely attributed to its fatty acid components. Lipids Health Dis. 2017, 16, 186. [Google Scholar] [CrossRef] [PubMed]
  71. Tan, M.-J.; Ye, J.-M.; Turner, N.; Hohnen-Behrens, C.; Ke, C.-Q.; Tang, C.-P.; Chen, T.; Weiss, H.-C.; Gesing, E.-R.; Rowland, A. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem. Biol. 2008, 15, 263–273. [Google Scholar] [CrossRef]
  72. Popovich, D.G.; Li, L.; Zhang, W. Bitter melon (Momordica charantia) triterpenoid extract reduces preadipocyte viability, lipid accumulation and adiponectin expression in 3T3-L1 cells. Food Chem. Toxicol. 2010, 48, 1619–1626. [Google Scholar] [CrossRef]
  73. Roffey, B.W.; Atwal, A.S.; Johns, T.; Kubow, S. Water extracts from Momordica charantia increase glucose uptake and adiponectin secretion in 3T3-L1 adipose cells. J. Ethnopharmacol. 2007, 112, 77–84. [Google Scholar] [CrossRef]
  74. Shih, C.-C.; Lin, C.-H.; Lin, W.-L.; Wu, J.-B. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. J. Ethnopharmacol. 2009, 123, 82–90. [Google Scholar] [CrossRef] [PubMed]
  75. Yibchok-Anun, S.; Adisakwattana, S.; Yao, C.Y.; Sangvanich, P.; Roengsumran, S.; Hsu, W.H. Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. Biol. Pharm. Bull. 2006, 29, 1126–1131. [Google Scholar] [CrossRef] [PubMed]
  76. Xin-Yi, H.E.; Liu, Z.H. Study on HTS Anti-diabetic Antagonists from Momordica charantia L. Food Sci. 2007, 28, 313–316. (in Chinese). [Google Scholar]
  77. Kumar, R.; Balaji, S.; Uma, T.; Sehgal, P. Fruit extracts of Momordica charantia potentiate glucose uptake and up-regulate Glut-4, PPARγ and PI3K. J. Ethnopharmacol. 2009, 126, 533–537. [Google Scholar] [CrossRef] [PubMed]
  78. Han, J.H.; Tuan, N.Q.; Park, M.H.; Quan, K.T.; Oh, J.; Heo, K.S.; Na, M.; Myung, C.S. Cucurbitane Triterpenoids from the Fruits of Momordica Charantia Improve Insulin Sensitivity and Glucose Homeostasis in Streptozotocin-Induced Diabetic Mice. Mol. Nutr. Food Res. 2018, 62, 1700769. [Google Scholar] [CrossRef] [PubMed]
  79. Miura, T.; Kawata, T.; Takagi, S.; Nanpei, M.; Nakao, H.; Ishihara, E.; Ishida, T. Effect of Momordica charantia on Adenosine Monophosphate-activated Protein Kinase in Genetically Type 2 Diabetic Mice Muscle. J. Health Sci. 2009, 55, 805–808. [Google Scholar] [CrossRef]
  80. Zhu, Y.; Dong, Y.; Qian, X.; Cui, F.; Guo, Q.; Zhou, X.; Wang, Y.; Zhang, Y.; Xiong, Z. Effect of superfine grinding on antidiabetic activity of bitter melon powder. Int. J. Mol. Sci. 2012, 13, 14203–14218. [Google Scholar] [CrossRef]
  81. Hussain, M.S.; Lira, N.; Rashid, M.M.O.; Hossain, M.S.; Rahman, N. P5 Histological and antihyperlipidemic screening along with plasma uric acid reducing potential of ethanolic extract of Momordica charantia seeds on swiss albino mice model. Biochem. Pharmacol. 2017, 139, 126. [Google Scholar] [CrossRef]
  82. Xu, J.; Cao, K.; Feng, Z.; Liu, J. Benefits of the soluble and insoluble fractions of bitter gourd in mice fed a high-fat diet. J. Funct. Foods 2018, 42, 216–223. [Google Scholar] [CrossRef]
  83. Ahmed, I.; Lakhani, M.; Gillett, M.; John, A.; Raza, H. Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats. Diabetes Res. Clin. Pract. 2001, 51, 155–161. [Google Scholar] [CrossRef]
  84. Welihinda, J.; Arvidson, G.; Gylfe, E.; Hellman, B.; Karlsson, E. The insulin-releasing activity of the tropical plant Momordica charantia. Acta Biol. Med. Ger. 1982, 41, 1229–1240. [Google Scholar]
  85. Senanayake, G.V.; Maruyama, M.; Shibuya, K.; Sakono, M.; Fukuda, N.; Morishita, T.; Yukizaki, C.; Kawano, M.; Ohta, H. The effects of bitter melon (Momordica charantia) on serum and liver triglyceride levels in rats. J. Ethnopharmacol. 2004, 91, 257–262. [Google Scholar] [CrossRef] [PubMed]
  86. Jayasooriya, A.P.; Sakono, M.; Yukizaki, C.; Kawano, M.; Yamamoto, K.; Fukuda, N. Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. J. Ethnopharmacol. 2000, 72, 331–336. [Google Scholar] [CrossRef]
  87. El Batran, S.A.E.S.; El-Gengaihi, S.E.; El Shabrawy, O.A. Some toxicological studies of Momordica charantia L. on albino rats in normal and alloxan diabetic rats. J. Ethnopharmacol. 2006, 108, 236–242. [Google Scholar] [CrossRef] [PubMed]
  88. Pan, X.-D.; Wang, H.-H.; Bing, H.-E.; Liu, J.-Y.; Cao, C.-M.; Zang, L.-Q. Effect of Water Extracts from Momordica charantia on Blood Lipids in Hyperlipidemic Mice. Chin. J. Exp. Tradit. Med. Form. 2013, 14, 265–267. [Google Scholar]
  89. Rosen, E.D.; Spiegelman, B.M. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006, 444, 847. [Google Scholar] [CrossRef] [PubMed]
  90. Shobha, C.R.; Prashant, V.; Akila, P.; Chandini, R.; Suma, M.N.; Basavanagowdappa, H. Fifty percent ethanolic extract of Momordica charantia inhibits adipogenesis and promotes adipolysis in 3T3-L1 pre-adipocyte cells. Rep. Biochem. Mol. Boil. 2017, 6, 22–32. [Google Scholar]
  91. Lefterova, M.I.; Lazar, M.A. New developments in adipogenesis. Trends Endocrinol. Metab. 2009, 20, 107–114. [Google Scholar] [CrossRef] [PubMed]
  92. Nerurkar, P.V.; Lee, Y.-K.; Nerurkar, V.R. Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC Complement. Altern. Med. 2010, 10, 34. [Google Scholar] [CrossRef] [PubMed]
  93. Chandra, M.; Miriyala, S.; Panchatcharam, M. PPARγ and its role in cardiovascular diseases. PPAR Res. 2017, 2017. [Google Scholar] [CrossRef]
  94. Zhang, Y.; Li, H. Three Important Transcription Factors Related to Lipogenesis and Adipogenesis in Mammal. J. Northeast Agric. Univ. 2010, 17, 62–75. [Google Scholar]
  95. Wang, L.; Na, W.; Wang, Y.; Wang, Y.; Wang, N.; Wang, Q.; Li, Y.; Li, H. Characterization of chicken PPARγ expression and its impact on adipocyte proliferation and differentiation. Hereditas 2012, 34, 454–464. [Google Scholar] [CrossRef] [PubMed]
  96. Li, Y.; Jin, D.; Xie, W.; Wen, L.; Chen, W.; Xu, J.; Ding, J.; Ren, D. PPAR-γ and Wnt regulate the differentiation of MSCs into adipocytes and osteoblasts respectively. Curr. Stem Cell Res. Ther. 2018, 13, 185–192. [Google Scholar] [CrossRef] [PubMed]
  97. Arner, P. The adipocyte in insulin resistance: Key molecules and the impact of the thiazolidinediones. Trends Endocrin. Met. 2003, 14, 137–145. [Google Scholar] [CrossRef]
  98. Fürnsinn, C.; Waldhäusl, W. Thiazolidinediones: Metabolic actions in vitro. Diabetologia 2002, 45, 1211–1223. [Google Scholar] [CrossRef] [PubMed]
  99. Hwang, J.-T.; Kwon, D.Y.; Yoon, S.H. AMP-activated protein kinase: A potential target for the diseases prevention by natural occurring polyphenols. N. Biotechnol. 2009, 26, 17–22. [Google Scholar] [CrossRef]
  100. Hwang, J.T.; Lee, M.S.; Kim, H.J.; Sung, M.J.; Kim, H.Y.; Kim, M.S.; Kwon, D.Y. Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-γ signal pathways. Phytother. Res.: Int. J. Pharmacol. Toxicol. Eval. Nat. Prod. Deriv.) 2009, 23, 262–266. [Google Scholar] [CrossRef]
  101. Watson, R.T.; Pessin, J.E. Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog. Horm. Res. 2001, 56, 175–193. [Google Scholar] [CrossRef]
  102. Iseli, T.J.; Turner, N.; Zeng, X.-Y.; Cooney, G.J.; Kraegen, E.W.; Yao, S.; Ye, Y.; James, D.E.; Ye, J.-M. Activation of AMPK by bitter melon triterpenoids involves CaMKKβ. PLoS ONE 2013, 8, e62309. [Google Scholar] [CrossRef]
  103. Klomann, S.D.; Mueller, A.S.; Pallauf, J.; Krawinkel, M.B. Antidiabetic effects of bitter gourd extracts in insulin-resistant db/db mice. Br. J. Nutr. 2010, 104, 1613–1620. [Google Scholar] [CrossRef] [Green Version]
  104. Chanda, J.; Mukherjee, P.K.; Biswas, R.; Malakar, D.; Pillai, M. Study of pancreatic lipase inhibition kinetics and LC–QTOF–MS-based identification of bioactive constituents of Momordica charantia fruits. Biomed. Chromatogr. 2019, 33, e4463. [Google Scholar] [CrossRef] [PubMed]
  105. Baldwa, V.S.; Bhandari, C.M.; Pangaria, A.; Goyal, R.K. Clinical Trial in Patients with Diabetes Mellitus of an Insulin-like Compound Obtained from Plant Source. Ups. J. Med. Sci. 1977, 82, 39–41. [Google Scholar] [CrossRef] [PubMed]
  106. Srivastava, Y.; Venkatakrishna-Bhatt, H.; Verma, Y.; Venkaiah, K.; Raval, B. Antidiabetic and adaptogenic properties of Momordica charantia extract: An experimental and clinical evaluation. Phytother. Res. 1993, 7, 285–289. [Google Scholar] [CrossRef]
  107. Welihinda, J.; Karunanayake, E.; Sheriff, M.; Jayasinghe, K. Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J. Ethnopharmacol. 1986, 17, 277–282. [Google Scholar] [CrossRef]
  108. Leung, L.; Birtwhistle, R.; Kotecha, J.; Hannah, S.; Cuthbertson, S. Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): A mini review. Br. J. Nutr. 2009, 102, 1703–1708. [Google Scholar] [CrossRef] [PubMed]
  109. Raman, A.; Lau, C. Anti-diabetic properties and phytochemistry of Momordica charantia L.(Cucurbitaceae). Phytomedicine 1996, 2, 349–362. [Google Scholar] [CrossRef]
  110. Nadkarni, N.; D’Cruz, S.; Sachdev, A. Hematemesis due to bitter melon (Momordica charantia) extract-induced gastric ulcerations. Indian J. Gastroenterol. 2010, 29, 43–44. [Google Scholar] [CrossRef] [PubMed]
  111. Zhang, Y.; Li, J.X.; Zhang, M.W.; Liao, S.T. Processing technology for a bitter gourd granulated solid beverage. Sci. Technol. Food Ind. 2006, 27, 108–109. [Google Scholar]
  112. Ji, H.F.; Zhang, L.W.; Zhang, Y.; Sun, K.X. Study on bitter melon health noddle. Sci. Technol. Food Ind. 2009, 30, 201–204. [Google Scholar]
  113. Gao, X.L.; Jia, X.H.; Zhang, H. Technology of Compound Sausage with Momordica Charantia. Food Ferment. 2012, 6, 70–73. [Google Scholar]
  114. Wang, B.Y.; Liu, Y.; Chen, J.N. Study on processing technology of bitter melon peanut low sugar health drink. Food Nutr. Chin. 2010, 6, 57–61. [Google Scholar]
  115. Zhao, G.-L.; Huo, L.-F. A research on the manufacture of balsam pear-apricot compound juice. Food Res. Dev. 2008, 10, 70–73. [Google Scholar]
  116. Zhang, Y.; Qiu, Y.Q.; Liao, S.T.; Zhang, M.W. Development of new type bitter melon yogurt without sugar. Food Sci. Technol. 2006, 31, 79–82. [Google Scholar]
  117. Liu, Z.; Zhang, H.K.; Liu, S.S.; She, S.W. Preparation of Solid Beverage of Effervescent Tablet from Bitter Gourd Powder. Food Ind. 2011, 2, 31–34. [Google Scholar]
  118. Zhang, Y.; Qiu, Y.Q.; Chi, J.W.; Zhang, M.W. Technology of compound beverage from bitter gourd and milk. Food Ind. 2005, 1, 28–30. [Google Scholar]
  119. Zhao, Y.; Shi, Q.-L.; Wang, X.-Y. Processing technology of balsam pear and Platycodon grandiflorum healthy compound beverage. Sci. Technol. Food Ind. 2008, 29, 210–213. [Google Scholar]
  120. Mou-quan, L.; Meilan, K. Research on the Technology of Beverage-preparation Combined with Ponkan and Balsam Pear. J. Anhui Agric. Sci. 2009, 6, 2713–2714. [Google Scholar]
Ijerph 16 03251 g001 550
Figure 1. Chemical structure of saponins and triterpenes isolated from M. charantia.
Figure 1. Chemical structure of saponins and triterpenes isolated from M. charantia.
Ijerph 16 03251 g001
Ijerph 16 03251 g002 550
Figure 2. Chemical structure of phenolics and flavonoids isolated from M. charantia.
Figure 2. Chemical structure of phenolics and flavonoids isolated from M. charantia.
Ijerph 16 03251 g002
Ijerph 16 03251 g003 550
Figure 3. Chemical structure of fatty acids isolated from M. charantia.
Figure 3. Chemical structure of fatty acids isolated from M. charantia.
Ijerph 16 03251 g003
Ijerph 16 03251 g004 550
Figure 4. Possible mechanisms contributing to the inhibition of fat synthesis and glucose utilization of M. charantia. M. charantia stimulates glucose transporter 4 (GluT-4) to migrate to the cell membrane and mediate glucose uptake by increasing adiponectin, and the adenosine monophosphate-activated protein kinase (AMPK) activity. In addition, M. charantia blocks the expression of PPARγ, and PPARγ downstream pathway including C/EBPα and PI3K to reduce the accumulation of fat.
Figure 4. Possible mechanisms contributing to the inhibition of fat synthesis and glucose utilization of M. charantia. M. charantia stimulates glucose transporter 4 (GluT-4) to migrate to the cell membrane and mediate glucose uptake by increasing adiponectin, and the adenosine monophosphate-activated protein kinase (AMPK) activity. In addition, M. charantia blocks the expression of PPARγ, and PPARγ downstream pathway including C/EBPα and PI3K to reduce the accumulation of fat.
Ijerph 16 03251 g004
Ijerph 16 03251 g005 550
Figure 5. Possible mechanisms contributing to the auxiliary lipid-lowering activity of M. charantia. M. charantia reduce the elevated levels of serum cholesterol, phospholipids, triglyceride (TG), and low-density lipoprotein (LDL). On the contrary, M. charantia increases the high-density lipoprotein (HDL) level by elevating lipid flow in the tissues.
Figure 5. Possible mechanisms contributing to the auxiliary lipid-lowering activity of M. charantia. M. charantia reduce the elevated levels of serum cholesterol, phospholipids, triglyceride (TG), and low-density lipoprotein (LDL). On the contrary, M. charantia increases the high-density lipoprotein (HDL) level by elevating lipid flow in the tissues.
Ijerph 16 03251 g005
Table
Table 1. Anti-obesity functions of bitter gourd (M. charantia) crude extract.
Table 1. Anti-obesity functions of bitter gourd (M. charantia) crude extract.
FunctionDownregulationUpregulationReferences
Inhibition of fat synthesispAkt, tAktpAMPK, tAMPK[71]
adiponectin[72]
PPARγ, adiponectin [73]
leptinGLUT-4[74]
Promotion of glucose utilizationinsulin resistance [75]
PPARδ[76]
GLUT-4[77]
glucose utilization[78]
AMPK[79]
fasting plasma glucose [80]
Auxiliary lipid-lowering activitycholesterol, TG [81]
TG [82]
cholesterol, TGHDL[83]
TGinsulin sensitivity[84]
TGHDL[85]
HDL[86]
cholesterol, TG [87]
TC, TG [88]
TG: triglyceride; TC: total cholesterol; HDL: high-density lipoprotein; AMPK: adenosine monophosphate-activated protein kinase; GLUT-4: glucose transporter 4; PPAR: Peroxisome proliferator-activated receptor; Akt: Protein kinase B.

Share and Cite

MDPI and ACS Style

Fan, M.; Kim, E.-K.; Choi, Y.-J.; Tang, Y.; Moon, S.-H. The Role of Momordica charantia in Resisting Obesity. Int. J. Environ. Res. Public Health 2019, 16, 3251. https://doi.org/10.3390/ijerph16183251

AMA Style

Fan M, Kim E-K, Choi Y-J, Tang Y, Moon S-H. The Role of Momordica charantia in Resisting Obesity. International Journal of Environmental Research and Public Health. 2019; 16(18):3251. https://doi.org/10.3390/ijerph16183251

Chicago/Turabian Style

Fan, Meiqi, Eun-Kyung Kim, Young-Jin Choi, Yujiao Tang, and Sang-Ho Moon. 2019. "The Role of Momordica charantia in Resisting Obesity" International Journal of Environmental Research and Public Health 16, no. 18: 3251. https://doi.org/10.3390/ijerph16183251

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop